In case of predicted and previously experienced difficult airway, we recommend informing the patient adequately and obtaining consent for specific procedures (e. g. awake intubation), and an alert form should be given to the patient in case of future procedures requiring airway management. (1C)

In patients with known chronic kidney disease (CKD), we recommend quantifying the estimated glomerular filtration rate (eGFR) and proteinuria before surgery for risk stratification regarding postoperative acute kidney injury (AKI) and worsening of CKD. (1C)

We suggest considering NT-Pro BNP testing combined with eGFR to add additional information on risk stratification for postoperative acute kidney injury (AKI) and worsening of CKD. (2C)

In elective procedures, we suggest that the perioperative continuation of antithrombotic therapy should be weighed against the bleeding risk of surgery, patientrelated factors, and the specific antithrombotic medication. (2C)

We recommend continuing antiplatelet therapy for 6 months after elective percutaneous intervention and 12 months after an urgent coronaryintervention. In the case of drug-coated balloon angioplasty, the duration of dual antiplatelet therapy could vary from a minimum of 1 month to a maximum of 12 months, depending on the status of the disease (stable vs. unstable, chronic vs. acute), the dimension of the occluded vessel, presence of in-stent restenosis, type of stenosed stent and bleeding risk. (1C)

We recommend managing anticoagulant medication before an emergency/urgent procedure based on its pharmacokinetic characteristics, reversal agent availability, the patient’s renal function and the likelihood of major bleeding (1A)

We suggest that the bleeding risk should be balanced with the thrombotic risk to assess the necessity of withdrawing the anticoagulant or antiplatelet therapy. (2C)

Wesuggestthatpatientswithpreviouspercutaneouscoronaryintervention require a careful risk–benefitassessmenttomanageperioperative antiplatelettherapy.(2C)

We suggest that the preoperative evaluation of patients undergoing noncardiac surgery should include an educational program for patients and their caregivers on the perioperative handling of their antithrombotic therapy. (2C)

We suggest that the perioperative assessment of coagulation status should be implemented through thromboelastometry and thromboelastography in patients with cirrhosis and significant coagulopathy, as well as in a hypercoagulability state with tranexamic acid administration. (2C)